This site is intended for US health care professionals.
01. Foundational / Icons / 32x32px/Menu @1x Open Menu 01. Foundational / Icons / 32x32px/Close @1x Close Menu

Burden of disease

Pneumococcal pneumonia and IPD are a serious risk for adult patients1-4

Pneumococcal pneumonia is the most common clinical manifestation of pneumococcal disease in adults.5 It leads to ~225,000 US hospitalizations annually and is estimated to account for 10 to 30% of all adult community-acquired pneumonia (CAP) cases in the US.5,6 CAP occurs when someone develops pneumonia outside of a hospital.7

Pneumococcal pneumonia leads to ~225,000 hospitalizations annually in the US6 

The same bacteria that cause pneumococcal pneumonia, Streptococcus pneumoniae, can invade normally sterile sites in the body, such as the blood or cerebrospinal fluid. When this occurs, it is referred to as IPD. IPD is a serious illness that can lead to hospitalization, complications including bacteremia and meningitis, and sometimes death.5

In the US, IPD is ~6x more likely to lead to death in adults over the age of 50, compared to those aged 18-49.8-12,a

Annual rate of IPD in US adults, 2019-20238-12,a

The Annual Rate of IPD Cases per 100,000: 4.3 in Ages 18-49, 12.7 in Ages 50-64, 17.3 in Ages 65+. The Rates of IPD for Adults Aged 50-64 Years Were ~3x Higher Than Adults 18-49 and ~4X Higher for Adults Aged 65+ Than Adults 18-49 Years.The Annual Rate of IPD Cases per 100,000: 4.3 in Ages 18-49, 12.7 in Ages 50-64, 17.3 in Ages 65+. The Rates of IPD for Adults Aged 50-64 Years Were ~3x Higher Than Adults 18-49 and ~4X Higher for Adults Aged 65+ Than Adults 18-49 Years.

Share with health care professionals

aBased on CDC ABC surveillance data from the years 2019–2023, representing ~35 million persons and 10 states across the US. Regional variations may exist.6,8-12

ABC, Active Bacterial Core; CAP, community acquired pneumonia; CDC, Centers for Disease Control and Prevention; IPD, invasive pneumococcal disease; US, United States.

References:

  1. ABCs bact facts interactive data dashboard. SPN serotypes 1998-2023. Centers for Disease Control and Prevention. August 21, 2025. Accessed August 27, 2025. https://www.cdc.gov/abcs/bact-facts/data-dashboard.html
  2. Grant LR, Meche A, McGrath L, et al. Risk of pneumococcal disease in US adults by age and risk profile. Open Forum Infect Dis. 2023;10(5):ofad192. Doi:10.1093/ofid/ofad192

  3. Grant LR, Meche A, McGrath L, et al. Supplementary material to: Risk of pneumococcal disease in US adults by age and risk profile. Open Forum Infect Dis. 2023;10(5):ofad192. Doi:10.1093/ofid/ofad192

  4. Clinical features of pneumococcal disease. Centers for Disease Control and Prevention. February 6, 2024. Accessed August 1, 2025. https://www.cdc.gov/pneumococcal/hcp/clinical-signs/

  5. Gierke R, Wodi P, Kobayashi M. Epidemiology and Prevention of Vaccine-Preventable Diseases (Pink Book). 14th edition. Chapter 17: Pneumococcal disease. Centers for Disease Control and Prevention. May 1, 2024. Accessed August 15, 2025. https://www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-17-pneumococcal-disease.html
  6. Kobayashi M, Leidner AJ, Gierke R, et al. Expanded recommendations for use of pneumococcal conjugate vaccines among adults aged ≥50 years: recommendations of the Advisory Committee on Immunization Practices — United States, 2024. MMWR Morb Mortal Wkly Rep. 2025;74(1):1-8. doi:10.15585/mmwr.mm7401a1
  7. About pneumonia. Centers for Disease Control and Prevention. October 7, 2024. Accessed October 14, 2024. https://www.cdc.gov/pneumonia/about/


  8. Active Bacterial Core surveillance (ABCs) report, Emerging Infections Program network, Streptococcus pneumoniae, 2019. Centers for Disease Control and Prevention. Updated June 16, 2021. Accessed August 1, 2025. https://www.cdc.gov/abcs/downloads/SPN_Surveillance_Report_2019.pdf

  9.  Active Bacterial Core surveillance (ABCs) report, Emerging Infections Program network, Streptococcus pneumoniae, 2020. Centers for Disease Control and Prevention. Updated September 20, 2022. Accessed August 1, 2025. https://stacks.cdc.gov/view/cdc/140328

  10. Active Bacterial Core surveillance (ABCs) report, Emerging Infections Program network, Streptococcus pneumoniae, 2021. Centers for Disease Control and Prevention. Updated June 2, 2023. Accessed August 4, 2025. https://www.cdc.gov/abcs/downloads/SPN_Surveillance_Report_2021.pdf
  11. Active Bacterial Core surveillance (ABCs) report, Emerging Infections Program network, Streptococcus pneumoniae, 2022. Centers for Disease Control and Prevention. Updated July 5, 2024. August 1, 2025. https://www.cdc.gov/abcs/downloads/SPN_Surveillance_Report_2022.pdf


  12. Active Bacterial Core surveillance (ABCs) report, Emerging Infections Program network, Streptococcus pneumoniae, 2023. Centers for Disease Control and Prevention. Updated March 20, 2025. Accessed July 28, 2025. https://www.cdc.gov/abcs/downloads/SPN_Surveillance_Report_2023.pdf
patientSite

By clicking on this link, you will be leaving Merck Vaccines.

Cancel
Proceed
Cancel
Proceed

Indications

CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) is indicated for:

  • active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in individuals 18 years of age and older.
  • active immunization for the prevention of pneumonia caused by S. pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in individuals 18 years of age and older.

The indication for the prevention of pneumonia caused by S. pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B is approved under accelerated approval based on immune responses as measured by opsonophagocytic activity (OPA). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Select Safety Information

Do not administer CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) to individuals with a history of a severe allergic reaction (eg, anaphylaxis) to any component of CAPVAXIVE or to diphtheria toxoid.
 
Individuals with altered immunocompetence, including those receiving immunosuppressive therapy, may have a reduced immune response to CAPVAXIVE.
 
The most commonly reported (>10%) solicited adverse reactions in individuals 18 through 49 years of age who received CAPVAXIVE were: injection-site pain (73.1%), fatigue (36.0%), headache (27.5%), myalgia (16.4%), injection-site erythema (13.8%), and injection-site swelling (13.3%).
 
The most commonly reported (>10%) solicited adverse reactions in individuals 50 years of age and older who received CAPVAXIVE were: injection-site pain (41.2%), fatigue (19.7%), and headache (11.0%).
 
Vaccination with CAPVAXIVE may not protect all vaccine recipients.

Before administering CAPVAXIVE, please read the accompanying Prescribing Information. The Patient Information also is available.

Indications

CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) is indicated for:

  • active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in individuals 18 years of age and older.
  • active immunization for the prevention of pneumonia caused by S. pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in individuals 18 years of age and older.

The indication for the prevention of pneumonia caused by S. pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B is approved under accelerated approval based on immune responses as measured by opsonophagocytic activity (OPA). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) is indicated for:

  • active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A,

CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) is indicated for:

  • active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A,

Select Safety Information

Do not administer CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) to individuals with a history of a severe allergic reaction (eg, anaphylaxis) to any component of CAPVAXIVE or to diphtheria toxoid.
 
Individuals with altered immunocompetence, including those receiving immunosuppressive therapy, may have a reduced immune response to CAPVAXIVE.
 
The most commonly reported (>10%) solicited adverse reactions in individuals 18 through 49 years of age who received CAPVAXIVE were: injection-site pain (73.1%), fatigue (36.0%), headache (27.5%), myalgia (16.4%), injection-site erythema (13.8%), and injection-site swelling (13.3%).
 
The most commonly reported (>10%) solicited adverse reactions in individuals 50 years of age and older who received CAPVAXIVE were: injection-site pain (41.2%), fatigue (19.7%), and headache (11.0%).
 
Vaccination with CAPVAXIVE may not protect all vaccine recipients.

Before administering CAPVAXIVE, please read the accompanying Prescribing Information. The Patient Information also is available.

Do not administer CAPVAXIVE to individuals with a history of a severe

Do not administer CAPVAXIVE to individuals with a history of a severe allergic reaction (eg, anaphylaxis) to any component of CAPVAXIVE or to diphtheria toxoid.

Individuals with altered immunocompetence, including those receiving immunosuppressive therapy, may have a reduced immune response to CAPVAXIVE.